Related references
Note: Only part of the references are listed.Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters
Carlie A. Black et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2021)
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia
Benjamin J. Dorfman et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2021)
Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors
Yifei Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Clinical development of valbenazine for tics associated with Tourette syndrome
Robert H. Farber et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2021)
Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers
Frank Schneider et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
Nannan Li et al.
FRONTIERS IN PHARMACOLOGY (2019)
Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters
Kevin G. Mulvihill
NEUROCHEMISTRY INTERNATIONAL (2019)
VMAT2 inhibitors for the treatment of tardive dyskinesia
Laura M. Scorr et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2018)
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia
Harini Sarva et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Similarity of the dog and human gut microbiomes in gene content and response to diet
Luis Pedro Coelho et al.
MICROBIOME (2018)
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
Stephen M. Stahl
CNS SPECTRUMS (2018)
Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease
Kelly M. Lohr et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2017)
Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis
Maren Carbon et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites
Dimitri E. Grigoriadis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine
Heather Skor et al.
DRUGS IN R&D (2017)
Dopamine depleters in the treatment of hyperkinetic movement disorders
Joseph Jankovic
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Valbenazine granted breakthrough drug status for treating tardive dyskinesia
Thomas Mueller
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Duloxetine-Associated Tardive Dyskinesia Resolved With Fluvoxamine A Case Report
Yakup Albayrak et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2012)
Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors
Zhangyu Yao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
Vesicular Monoamine Transporters: Structure-Function, Pharmacology, and Medicinal Chemistry
Kandatege Wimalasena
MEDICINAL RESEARCH REVIEWS (2011)
Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches
Natilie A. Hosea et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Fluorine in medicinal chemistry
Sophie Purser et al.
CHEMICAL SOCIETY REVIEWS (2008)
Preclinical pharmacokinetics: An approach towards safer and efficacious drugs
SS Singh
CURRENT DRUG METABOLISM (2006)
Fluorine in medicinal chemistry
HJ Böhm et al.
CHEMBIOCHEM (2004)
Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesteryl ester transfer protein
MA Massa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Share Paper
